Nvidia and Eli Lilly Partner on AI Drug Discovery Lab with USD 1 Billion Investment

Nvidia plans to invest USD 1 billion over five years in a joint laboratory with pharmaceutical company Eli Lilly. The collaboration aims to integrate advanced artificial intelligence directly into laboratory workflows for drug discovery.

Credit: NVIDIA

The new facility will be built in Silicon Valley. It will utilise Nvidia’s BioNeMo platform, a suite of AI models designed to analyse molecular structures and identify drug candidates.

The partnership involves a two-way knowledge transfer. Nvidia’s AI engineers will gain practical experience with laboratory equipment, while Eli Lilly scientists will refine algorithms and AI systems for specific research tasks.

Credit: NVIDIA

Jensen Huang, founder and Chief Executive Officer of Nvidia, stated, "AI is transforming every industry, and its most profound impact will be in life sciences." He added that both companies "are bringing together the best of our industries to invent a new blueprint for drug discovery — one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made."

The initiative allows Nvidia to expand beyond its core market of AI accelerator chips into the global pharmaceutical sector, valued at USD 1.3 trillion.

To establish the necessary infrastructure, Nvidia is collaborating with Thermo Fisher Scientific. This partnership aims to integrate laboratory instruments directly with its DGX Spark AI computers, enabling automated control.

A separate collaboration with Multiply Labs focuses on training robots to perform complex research procedures. This work is intended to enable laboratories to run experiments with minimal human involvement.

Kimberly Powell, Vice President of Health Care at Nvidia, stated, "Humans are the primary constraint on the speed of labs." This new partnership builds on a prior project where the companies constructed what they describe as he "most powerful supercomputer owned and operated by a pharmaceutical company."

This supercomputer is housed at Eli Lilly’s Indianapolis headquarters. Artificial intelligence has demonstrated an ability to generate novel molecular compounds.

However, translating these digital predictions into verified physical outcomes continues to present a challenge. The lab’s proposed closed-loop system is designed for AI to both propose drug candidates and, through robotic systems, execute experiments to validate them.

The integration of AI and biotechnology aims to reduce the typical decade-long, multibillion-dollar timeline for drug development. This could accelerate the creation of treatments for diseases, including cancer and Alzheimer’s.

---

• Nvidia is investing USD 1 billion over five years in a joint AI drug discovery laboratory with Eli Lilly.

• The facility will be located in Silicon Valley and will use Nvidia’s BioNeMo platform for molecular analysis.

• The collaboration includes partnerships with Thermo Fisher Scientific for automated instrument integration and Multiply Labs for training research robots.

Source: FORBES